Middle ear disorder

Summary

Middle ear disorder (MONDO:0003276) is a disease (an umbrella term covering 6 Mondo subtypes) and 9 clinical trials. Top therapeutic interventions include histamine, oxymetazoline, and pseudoephedrine. A subtype of auditory system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 6 Mondo subtypes
• Clinical trials: 9

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	middle ear disorder
Mondo ID	MONDO:0003276
DOID	DOID:5100
ICD-10-CM	H65-H75
NCIT	C27065
SNOMED CT	68996008
UMLS	C0271428
MedGen	124401
Anatomy (UBERON)	UBERON:0001756
Is cancer (heuristic)	no

Also known as: disease of middle ear · disease or disorder of middle ear · disorder of middle ear · middle ear disease · middle ear disease or disorder · middle Ear disorder

Disease family

This is a subtype of auditory system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › middle ear disorder

Related subtypes (10): discharging ear, dislocation of ear ossicle, adhesive otitis media, retrocochlear disease, inner ear disorder, external ear disorder, auditory system cancer, hearing disorder, inherited auditory system disease, auditory system benign neoplasm

Subtypes (6): necrosis of ear ossicle, tympanic membrane disorder, eustachian tube disorder, otitis media, cholesteatoma of middle ear, neoplasm of middle ear

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 9.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01925729	PHASE1	COMPLETED	TransMEM Gas Exchange – Project 1, Aim 2
NCT02554422	Not specified	COMPLETED	Objective Measurement of Ossicular Chain Mobility Using a Palpating Instrument Intraoperatively
NCT03297736	Not specified	UNKNOWN	Improved Otologic Implants on Demand Intraoperatively With 3D CAD/CAM Autografts
NCT04776967	Not specified	COMPLETED	Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study.
NCT04804098	Not specified	UNKNOWN	Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study.
NCT05055115	Not specified	UNKNOWN	Ph.D.-Project: Eustachian Tube Dysfunction: Causes, Diagnosis, Treatment, and Prognosis
NCT05085379	Not specified	WITHDRAWN	Optical Coherence Tomography of the Middle Ear Using Ossiview
NCT05813119	Not specified	COMPLETED	Efficacy of Digital Otoscope and Otoendoscope for Diagnosis of Middle Ear Pathology
NCT06434636	Not specified	COMPLETED	The Effect of Tranexamic Acid in Endoscopic and Microscopic Ear Surgery Cases on Surgeon Satisfaction

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
HISTAMINE	4	3
OXYMETAZOLINE	4	3
PSEUDOEPHEDRINE	4	1
CHEMBL443232	0	1